Skip to main content

QNTM DEADLINE: Investors of Quantum Biopharma Ltd. (QNTM) are Encouraged to Contact Kaplan Fox Before the Lead Plaintiff Deadline on February 23, 2026

CLICK HERE TO JOIN THE CASE

If you sold Quantum securities during the Class Period and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing mail@kaplanfox.com or dhall@kaplanfox.com, or by calling (800) 290-1952.

DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than February 23, 2026, to serve as a lead plaintiff for the purported class.  If you have losses, we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.

The complaint alleges that “spoofing” is a manipulative and illegal trading practice that involves submitting and then cancelling buy or sell orders without any genuine intent to execute them. 

The complaint alleges that during the Class Period, Defendants repeatedly entered thousands of spoofed sell orders designed to create the false impression in the market that Quantum’s stock price was falling and that these manipulative orders were calculated to (and successfully did) deceive or induce other investors to sell their holdings at artificially low prices. Further, the complaint alleges that Defendant’s purchased shares at these artificially depressed levels and positioned themselves to profit at the same time that investors were baited into selling shares at artificially depressed prices.

WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey.  With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand.  Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients.  For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.  Past results do not guarantee future outcomes.

If you have any questions about this Notice, your rights, or your interests, please contact:

CONTACT:
Donald R. Hall
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(212) 687-1980
dhall@kaplanfox.com

Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1560
Oakland, California 94612
(415) 772-4704
lking@kaplanfox.com

Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.

Recent Quotes

View More
Symbol Price Change (%)
AMZN  245.63
+4.07 (1.68%)
AAPL  257.13
-3.19 (-1.23%)
AMD  204.72
-5.30 (-2.52%)
BAC  56.50
+0.86 (1.55%)
GOOG  327.33
+4.90 (1.52%)
META  643.50
-5.19 (-0.80%)
MSFT  478.03
-5.44 (-1.13%)
NVDA  184.44
-4.67 (-2.47%)
ORCL  190.53
-2.31 (-1.20%)
TSLA  436.36
+4.94 (1.15%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.